JP2013006854A5 - - Google Patents

Download PDF

Info

Publication number
JP2013006854A5
JP2013006854A5 JP2012191753A JP2012191753A JP2013006854A5 JP 2013006854 A5 JP2013006854 A5 JP 2013006854A5 JP 2012191753 A JP2012191753 A JP 2012191753A JP 2012191753 A JP2012191753 A JP 2012191753A JP 2013006854 A5 JP2013006854 A5 JP 2013006854A5
Authority
JP
Japan
Prior art keywords
halogen atom
alkyl group
thio
hydrogen atom
glucitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012191753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013006854A (ja
JP5660094B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012191753A priority Critical patent/JP5660094B2/ja
Priority claimed from JP2012191753A external-priority patent/JP5660094B2/ja
Publication of JP2013006854A publication Critical patent/JP2013006854A/ja
Publication of JP2013006854A5 publication Critical patent/JP2013006854A5/ja
Application granted granted Critical
Publication of JP5660094B2 publication Critical patent/JP5660094B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012191753A 2009-04-16 2012-08-31 併用医薬 Expired - Fee Related JP5660094B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012191753A JP5660094B2 (ja) 2009-04-16 2012-08-31 併用医薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
JP2009100210 2009-04-16
JP2012191753A JP5660094B2 (ja) 2009-04-16 2012-08-31 併用医薬

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011540651A Division JP5077786B2 (ja) 2009-04-16 2010-04-16 併用医薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014245257A Division JP5910711B2 (ja) 2009-04-16 2014-12-03 併用医薬

Publications (3)

Publication Number Publication Date
JP2013006854A JP2013006854A (ja) 2013-01-10
JP2013006854A5 true JP2013006854A5 (enExample) 2013-05-30
JP5660094B2 JP5660094B2 (ja) 2015-01-28

Family

ID=42982643

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011540651A Active JP5077786B2 (ja) 2009-04-16 2010-04-16 併用医薬
JP2012191753A Expired - Fee Related JP5660094B2 (ja) 2009-04-16 2012-08-31 併用医薬
JP2014245257A Active JP5910711B2 (ja) 2009-04-16 2014-12-03 併用医薬
JP2015253932A Active JP6066144B2 (ja) 2009-04-16 2015-12-25 併用医薬

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011540651A Active JP5077786B2 (ja) 2009-04-16 2010-04-16 併用医薬

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014245257A Active JP5910711B2 (ja) 2009-04-16 2014-12-03 併用医薬
JP2015253932A Active JP6066144B2 (ja) 2009-04-16 2015-12-25 併用医薬

Country Status (30)

Country Link
US (1) US20120040898A1 (enExample)
EP (3) EP2419097B1 (enExample)
JP (4) JP5077786B2 (enExample)
KR (2) KR20150046382A (enExample)
CN (7) CN105343871A (enExample)
AR (1) AR076317A1 (enExample)
AU (1) AU2010237748B2 (enExample)
BR (1) BRPI1012539A2 (enExample)
CA (1) CA2755392A1 (enExample)
CY (2) CY1114703T1 (enExample)
DK (2) DK2419097T3 (enExample)
ES (2) ES2523408T3 (enExample)
HK (6) HK1217302A1 (enExample)
HR (2) HRP20131120T1 (enExample)
ME (2) ME02015B (enExample)
MX (1) MX2011010901A (enExample)
MY (3) MY183793A (enExample)
NZ (4) NZ606888A (enExample)
PH (3) PH12015500235A1 (enExample)
PL (2) PL2601949T3 (enExample)
PT (2) PT2419097E (enExample)
RS (2) RS53761B1 (enExample)
RU (2) RU2532330C2 (enExample)
SG (6) SG2014012405A (enExample)
SI (2) SI2419097T1 (enExample)
SM (1) SMT201500015B (enExample)
TW (3) TW201622720A (enExample)
UA (2) UA105216C2 (enExample)
WO (1) WO2010119990A1 (enExample)
ZA (1) ZA201106727B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
KR20110118668A (ko) 2009-02-13 2011-10-31 베링거 인겔하임 인터내셔날 게엠베하 1형 당뇨병, 2형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 sglt­2 억제제
DK2486029T3 (en) 2009-09-30 2015-08-24 Boehringer Ingelheim Int Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
IN2014DN09554A (enExample) 2012-05-17 2015-07-17 Transtech Pharma Llc
RU2015110979A (ru) * 2012-08-30 2016-10-20 Тайсо Фармасьютикал Ко., Лтд. Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
TW201513857A (zh) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
BR112017018329A2 (pt) * 2015-02-27 2018-08-07 The Asan Foundation composição para prevenir ou tratar calcificação de válvula, contendo inibidor de dpp-4
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
CA3041169A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
WO2018087132A1 (en) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11439689B2 (en) * 2016-11-14 2022-09-13 Kaohsiung Medical University Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
JP7425793B2 (ja) 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
CA3112510A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
US20030045553A1 (en) * 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
DK1385856T3 (da) * 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
KR20090023570A (ko) * 2006-06-29 2009-03-05 다이쇼 세이야꾸 가부시끼가이샤 C-페닐 1-티오글루시톨 화합물
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 1−チオ−d−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
CA2656847A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
CL2007003227A1 (es) * 2006-11-09 2008-07-04 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras.
EP2103607A4 (en) * 2006-12-14 2011-01-05 Taisho Pharmaceutical Co Ltd 1-phenyl-1-thio-D-GLUCITOLDERIVAT
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
CL2008002425A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.

Similar Documents

Publication Publication Date Title
RU2011146335A (ru) Фармацевтические композиции
US9487508B2 (en) SGC stimulators
JP2011504903A5 (enExample)
JP4643760B2 (ja) Dpp−iv阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬
JP2023541432A5 (enExample)
JP2008007519A5 (enExample)
CA2789665A1 (en) Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
CY1116799T1 (el) Προληψη της υπογλυκαιμιας σε ασθενεις με σακχαρωδη διαβητη τυπου 2
JP2014500295A5 (enExample)
JP2011509922A5 (enExample)
JP2007519649A5 (enExample)
JP2017505293A5 (enExample)
JP2005506352A5 (enExample)
CY1113755T1 (el) Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
JP2013508279A5 (enExample)
JP2014528464A5 (enExample)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
JP2011516428A5 (enExample)
JP2013518107A5 (enExample)
RU2013155586A (ru) [1,3]оксазины
JP2012530779A5 (enExample)
JP2016505637A5 (enExample)
JP2015172098A5 (enExample)
RU2015125300A (ru) Производные фенотиазина и их применение против туберкулеза
JP2016525104A5 (enExample)